Shares of Theravance Inc. (NASDAQ: THRX) rallied about 15% by afternoon trade after a federal advisory panel on Wednesday said that proposed lung treatment drug, Breo Ellipta, jointly developed by GlaxoSmithKline PLC and Theravance was not only effective but also safe and confirmed that it will approve the product . Breo Ellipta, which is meant to treat chronic obstructive pulmonary disease or COPD, is once-a-day inhalation drug.
Continue reading Major Movers on April 18; THRX, CLB, SNDK, EBAY, MS